Basic Sciences Archives
Vanderbilt University School of Medicine names renowned scholar Kuriyan as next dean of Basic Sciences
Jun. 29, 2022—Vanderbilt has named John Kuriyan, PhD, one of the world’s leading structural biologists, as its next dean of the School of Medicine Basic Sciences.
Bacterial battle in 3D
Jun. 2, 2022—Using imaging mass spectrometry and microscopy, Vanderbilt researchers visualized how staph bacteria modifies lipids in its membrane to evade immune system-mediated killing.
New faculty awards honor clinical, research, teaching missions
Jan. 6, 2022—The Office of Research, the Office of Faculty Affairs, and the Basic Sciences have created four new faculty awards named to honor and recognize past and current leadership in the clinical, educational, and research missions of Vanderbilt University School of Medicine.
Study sets framework for precision surveillance of colorectal cancer
Dec. 14, 2021—Vanderbilt research has revealed some of the mechanisms by which polyps develop into colorectal cancer, setting the framework for improved surveillance for the cancer utilizing precision medicine.
New marker for metaplasia
Oct. 14, 2021—A protein that transports water, called aquaporin 5, is expressed by cells undergoing changes that may increase risk for gastric cancer development, Vanderbilt researchers discovered.
Marnett stepping down as dean of VUSM Basic Sciences
Oct. 12, 2021—Lawrence Marnett, PhD, who has served as dean of Vanderbilt University’s School of Medicine Basic Sciences since its creation in 2016, will step down as dean effective June 30, 2022.
Molecular imaging of C. diff infection
Sep. 30, 2021—C. difficile — the leading cause of hospital-associated intestinal infections — induces a rapid influx of bile acids into the gut, which could provide a novel target for blocking infection.
Discovery offers insight for development of cancer therapies targeting mutant p53
Sep. 2, 2021—Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.
Potential protection from atherosclerosis
Aug. 19, 2021—Vanderbilt researchers have discovered a potential way to reduce atherosclerosis: blocking the modification of an HDL-associated enzyme by reactive molecules called isolevuglandins.
Expression atlas for cell regulators
Aug. 19, 2021—Vanderbilt researchers report a comprehensive tissue-specific atlas of protein and mRNA expression for p63 and p73, members of the p53 family signaling network that is the most frequent target of mutations in human cancers.
Researchers discover that protein switches functions to regulate DNA replication
Jul. 22, 2021—Vanderbilt biochemists have discovered what the DNA damage response protein RADX does — and how it does it.
Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma
Jul. 1, 2021—A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.
